We have attempted to make the dengue vaccine more affordable than other innovative vaccines Read more
Takeda oncology pipeline remains robust despite shift in focus from CAR-T to allogeneic cell therapies: GlobalData Read more
Takeda’s dengue vaccine candidate provides continued protection against dengue fever through 4.5 years in pivotal clinical trial Read more
Schneider Electric launches programme to increase access to renewable energy for pharmaceutical suppliers Read more
EMA approves label update for Takeda’s HYQVIA, expands use to treat secondary immunodeficiencies Read more
Key pipeline advancements to propel myelodysplastic syndromes market to $2.4 bn by 2028: GlobalData Read more